top of page

News & Press Releases

Join our Newsletter

To receive News as it is released, please sign up.

Thanks for submitting!

March 12, 2023

The technology was seized upon by the US government, which has provided Spectral with more than £65million of funding over the past ten years to research and develop DeepView for use on burn victims, many of whom suffer terribly from delayed diagnosis on treatment.

Feb 23, 2023

A new approach for burn wound assessment is being led by Dallas, Texas-based company SpectralMD, who are using AI and machine learning techniques to develop an imaging tool, the DeepView system, that can accurately predict the severity of burn injuries.

Feb 21, 2023

Spectral MD has partnered with the Royal College of Surgeons in Ireland's (RCSI) Skin Wounds and Trauma (SWaT) Research Centre, Prof. Zena Moore, Director; and Prof. Declan Patton, Deputy Director, at RCSI University of Medicine and Health Sciences, to execute the clinical study with Prof. John McDermott (Chief Clinical Investigator) and Prof. Seamus Sreenan (Sub Investigator), both of Connolly Hospital, and RCSI in Dublin, Ireland.

Jan 18, 2023

The four-week milestone in DFU reduction in the clinical treatment pathway for a DFU patient is meaningful to determine if alternative treatment is needed. The interim analysis was performed with an initial 100 U.S. adult subjects out of the targeted 200 subjects enrolled, and showed...

Nov 9, 2022

As Chief Operating Officer of Spectral MD, reporting to CEO Wensheng Fan, Dr. Pagoulatos will accelerate growth and operational performance of the Company with specific focus on scientific research, engineering, product development leading to global portfolio launch and clinical adoption.

Oct 5, 2022

Over one million people in the US and 250,000 in the UK seek evaluation for burn injuries in emergent or urgent care settings every year. A major component of the initial evaluation includes burn wound assessment. Literature shows that burn care providers typically assess the depth of burn wounds incorrectly in about 25-30% of injuries, partly because burn wound evaluation has no adjunctive labs to aid in the determination of healing versus non-healing burn wounds.

Sept 27, 2022

LONDON, U.K AND DALLAS, TX, U.S. Spectral MD Holdings, Ltd. (AIM: SMD), a predictive analytics company with proprietary AI and optical technology for faster and more accurate treatment decisions in wound care, announces that at the AGM held earlier today, all resolutions were duly passed.

Sept 20, 2022

Operational highlights, post-period highlights, and financial highlights.

Sept 1, 2022

The Company's AGM will take place at 9.30 am (CT) and 3.30 pm (BST) on 27 September 2022 and will be held as a hybrid meeting electronically, via the Investor Meet Company platform ("IMC") and physically, at the Company's corporate headquarters located at 2515 McKinney Avenue, Suite 1000, Dallas, TX 75201.

 

Any shareholder wishing to attend in person must register in advance by contacting the Company at [email protected]

Aug 30, 2022

Funding will accelerate commercialization pathway for Spectral MD's DeepView® technology. Click to read more.

July 7, 2022

As set forth in the Company's AIM Admission document, the Charter requires the Company's stockholders holding no less than 30 per cent. and no more than 50 per cent. of the Company's common stock of $0.001 par value each (the "Common Shares") to offer to purchase all of the outstanding Company's Common Shares from the other stockholders of the Company if they seek to purchase any additional Common Shares.

June 27, 2022

Spectral MD Wins Best Technology Award at Prestigious European Mediscience Awards Event in London

June 13, 2022

The study will collect data from up to 200 adult subjects across seven potential clinical sites to further develop DeepView®'s AI algorithm. Patient enrollment for the validation study began this month and is expected to complete in November 2022.

May 10, 2022

Spectral MD has been shortlisted for two awards at this year's European Mediscience Awards for: Best Technology Award and Best Newcomer Award. The European Mediscience Awards is the largest annual gathering of private and publicly quoted healthcare, biotech and life science companies in Europe recognizing achievements in the life sciences industry.

May 10, 2022

Annual Report

April 13, 2022

Seasoned marketing & commercialisation professional to help bolster commercialisation expertise.

March 21, 2022

All key operational milestones outlined at admission to AIM achieved in a transformational year for the Company.

March 9, 2022

Wensheng Fan, Chief Executive Officer, and Nils Windler, Chief Financial Officer, will provide a live presentation relating to the Company’s results via the Investor Meet Company platform on Monday, 21 March at 16:30hrs GMT.

February 4, 2022

Spectral MD Holdings, Ltd. (AIM: SMD), a predictive analytics company that develops proprietary AI algorithms and optical technology for faster and more accurate treatment decisions in wound care...

February 1, 2022

The Company intends to publish its audited preliminary results for the year ended 31 December 2021 by the end of March.

January 11, 2022

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them.

December 6, 2021

Former KCI (Acelity), 3M and Siemens Healthcare Vice President Nils Windler joins Spectral MD.  See more...

November 18, 2021

The IRB-approved multi-center study enroled a total of 150 adult subjects and was executed successfully and on schedule across six clinical sites in the U.S. The training study with data from all study subjects is expected to complete in December 2021.  See more...

November 16, 2021

The results of the first multi-center study using Spectral MD's burn imaging technology include 124 adult and pediatric participants. In adult participants, the performance with cross-validation from the AI model for identification of non-healing burn regions showed 92% accuracy, an improvement on the previously reported accurarcy of 91% for the DeepView® Wound Imaging Solution in early healing assessment of adults. In pediatric patients, the AI performance showed 88% accuracy, underlining how the technology is responding with significant reliability to variability in the study population.

October 20, 2021

Spectral MD Holdings, Ltd. (AIM: SMD), a predictive analytics company that develops proprietary AI algorithms and optical technology for faster and more accurate treatment decisions in wound care, announces the appointment of Stifel Nicolaus Europe Limited as Joint Broker alongside SP Angel Corporate Finance LLP, the existing Broker and Nominated Adviser, with immediate effect.

September 13, 2021

Spectral MD has achieved all the project milestones it set to be achieved by this time in 2021 and has achieved other important milestones ahead of schedule, including early receipt of increased U.S. Government grant funding of c. US $20 million post-IPO and progress on new burn and DFU patient studies.

September 7, 2021

Wensheng Fan, Chief Executive Officer, and Wan Lung Eng, Chief Financial Officer, will provide a live presentation relating to the Company’s interim results via the Investor Meet Company platform on Monday, 13 September at 16:30hrs BST.

September 6, 2021

This contract option funding of $18.8 million under Option 1B of Spectral MD’s current contract with BARDA follows the $20.6 million awarded under Option 1A which was exercised by BARDA in March 2021 to execute the first stage of the clinical training study at five sites to train the DeepView® AI algorithm.

August 9, 2021

Spectral MD welcomed physicians, clinical coordinators, and researchers from five clinical candidate sites across the United States to the kick-off event. Over the two-days, Spectral MD showcased its next generation, user-friendly DeepView® technology to physicians, clinical coordinators, and researchers from the five candidate sites.

July 15, 2021

TR-1: Standard form for notification of major holdings.

June 24, 2021

This Contract will support Spectral MD in advancing a new, multispectral imaging ("MSI") sensor intended to enable the development of a fully handheld version of DeepView™, Spectral MD's existing AI and MSI technology for early burn wound healing assessment, in a far-forward military environment.

June 22, 2021

Oversubscribed Placing for gross proceeds of £11.3 million (c.US$16 million).  Click to the summary and highlights here.

June 16, 2021

THIS ANNOUNCEMENT AND THE INFORMATION CONTAINED HEREIN IS RESTRICTED AND IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO OR FROM, THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, JAPAN, THE REPUBLIC OF IRELAND, THE REPUBLIC OF SOUTH AFRICA OR ANY OTHER JURISDICTION WHERE IT IS UNLAWFUL TO RELEASE, PUBLISH OR DISTRIBUTE THIS ANNOUNCEMENT.

THESE SECURITIES WILL BE OFFERED ONLY OUTSIDE OF THE UNITED STATES TO NON-U.S. PERSONS, PURSUANT TO THE PROVISIONS OF REGULATION S OF THE U.S. SECURITIES ACT OF 1933, AS AMENDED. THESE SECURITIES WILL NOT BE REGISTERED UNDER THE SECURITIES ACT, AND MAY NOT BE OFFERED OR SOLD IN THE UNITED STATES ABSENT REGISTRATION OR AN APPLICABLE EXEMPTION FROM THE REGISTRATION REQUIREMENTS. 

June 7, 2021

Wound care AI company, focused on predictive analytics for faster treatment decisions  to seek admission to AIM and raise funding through an IPO. 

April 20, 2021

A company using technology for assessing wounds is getting more funding.

April 7, 2021

Spectral MD receives funding to further develop its artificial intelligence for wound healing assessment.

February 2, 2021

Spectral MD's DeepView imaging device collected data from 124 Adult and Pediatric Subjects to further develop its burn wound-healing prediction AI Algorithm

Spectral MD and RCSI to Advance Care for Chronic Wounds

December 17, 2020

Spectral MD and Royal College of Surgeons in Ireland (RCSI) University of Medicine and Health Sciences Skin Wounds, and Trauma (SWaT) Research Center will collaborate to provide scientific oversight and assessment of the clinical value of Spectral MD's DeepView technology in chronic wounds

Spectral MD Initiates Multi-Center Clinical Study for Diabetic Foot Ulcer

December 17, 2020

Spectral MD's DeepView Wound Imaging System will collect critical data to further develop its multi-spectral imaging and artificial intelligence-based wound-healing prediction technology

Spectral MD Appoints Dr. Jeffrey Carter as Chief Medical Consultant and Wan Lung Eng as Chief Financial Officer

December 1, 2020

Spectral MD broadens the company's executive leadership team with the addition of two new members

Spectral MD and the American College of Cardiology to Advance Care for Critical Limb Ischemia

July 21, 2020

Spectral MD and the ACC will collaborate to provide scientific oversight and assessment of the clinical value of Spectral MD's DeepView technology to detect and assess critical limb ischemia

Spectral MD Names New CEO

June 29, 2020

Co-Founder Wensheng Fan, Spectral MD's Current COO, Promoted to CEO

Spectral MD and BARDA Agree to Start Enrollment in Clinics for Expanded Proof Of Concept Study (ePOC) Stage II Using the Company’s Improved DeepView SnapShot® Device

June 3, 2020

Spectral MD, Inc. (SMD) announced today that the Biomedical Advanced Research and Development Authority (BARDA) has agreed with SMD to proceed with Stage II enrollment for the ePOC after reviewing the performance of their next-generation imaging head in their Stage I ePOC study.

Spectral MD Welcomes Former Cleveland Clinic CEO Toby Cosgrove to the Spectral MD Board of Advisors

May 19, 2020

Toby Cosgrove joins the Spectral MD Board of Advisors and will assist all aspects of the Company's progression, including with burn and diabetic foot ulcer clinical trial and other strategic introductions.

New technology at UMC Burn Center

January 7, 2020

Fox 8 Live news talks to University Medical Center (UMC) Burn Center regarding burn wounds and how they are treated using DeepView®.

Credit: Fox 8 Local First

Modernizing wound care with Spectral MD, powered by Amazon SageMaker

August 15, 2019

Amazon Web Services (AWS) Machine Learning Blog

Spectral MD Receives Substantial Funding from BARDA for Continued Development of Spectral MD’s DeepView® Biomedical Imaging Device

July 23, 2019

Spectral MD receives $27 million under a 22-month contract, which can be extended for a total of up to $92 million

U.S. Invests In Burn Imaging Device For Mass Casualty Preparedness

July 19, 2019

CBRNE Central: Mass Casualty Preparedness Notable Contracts, Spectral MD

U.S. Department of Health and Human Services (HHS) sponsors development of portable, user-friendly burn imaging device

July 18, 2019

Program advances next-generation technology to improve care for burn patients.

Social Share

  • LinkedIn
  • Twitter
bottom of page